BrainScope Company, Inc.

The Healing Company Achieves Revenue of $8.9 Million for Fiscal 2023 and Positive Adjusted EBITDA for Chopra and Your Super

Retrieved on: 
Monday, October 23, 2023
Ratio, BrainScope Company, Inc., Dabur, Health, EBITDA, OTC, GAAP, Acquisition, Entrepreneurship, United, Quality of life, Growth, Travel, Immunity, USA Network, Partnership, Culture, Annual report, Ulva Belsham, Ayurveda, Appetite, Clothing, Hospital, Pharmaceutical industry, Retail, Chopra

NEW YORK, NY, Oct. 23, 2023 (GLOBE NEWSWIRE) -- The Healing Company Inc. (OTC: HLCO) today provided a business update and reported financial results for the fiscal year ended June 30, 2023.

Key Points: 
  • Chopra achieves three-fold sequential increase in revenue for the fiscal 2023 fourth quarter, and Your Super achieves positive adjusted EBITDA1 in fiscal 2023 for the first time in company history
    Collectively, The Healing Company portfolio served nearly half a million people this year, advancing its mission to bring integrated healing to the world
    NEW YORK, NY, Oct. 23, 2023 (GLOBE NEWSWIRE) -- The Healing Company Inc. (OTC: HLCO) today provided a business update and reported financial results for the fiscal year ended June 30, 2023.
  • The Healing Company posted revenue of $8.9 million for fiscal 2023, and sequential revenue for the fiscal 2023 fourth quarter increased by 5% to $3.3 million compared to the third quarter of fiscal 2023.
  • Operating expenses were reduced by 11% for the fiscal 2023 fourth quarter compared to the third quarter of fiscal 2023, and annualized operating expenses were further reduced by nearly $1.8 million in August 2023.
  • “We are pleased to report that we achieved record revenue and positive adjusted EBITDA1 in each segment, excluding one-time, non-recurring expenses, driven by prudent investment, disciplined growth, and reduced operating expenses,” said Simon Belsham, CEO and Co-Founder of The Healing Company.

The Estée Lauder Companies Highlights Key Epigenetics & Multi-Ethnic Translational Clinical Research at 33rd IFSCC Congress

Retrieved on: 
Thursday, October 12, 2023
Congress, Circadian rhythm, Human, Senior, NYSE, Engineering, Doctor of Philosophy, International Federation of Societies of Cosmetic Chemists, Pigment, Biology, ELC, EL, MD, Publishing, Laboratory, PIE, PIH, BrainScope Company, Inc., D, Ageing, Research fellow, Home economics, Environment, Chemistry, Society, Science, MicroRNA, African Americans, Skin, Woman, Research, Physics, Pharmaceutical industry, Nursing, List of life sciences

NEW YORK, Oct. 12, 2023 /PRNewswire/ -- The Estée Lauder Companies Inc. (ELC) (NYSE: EL) shared its latest clinical research findings in an invited keynote address and podium presentation at the 33rd International Federation of Societies of Cosmetic Chemists (IFSCC) Congress, held in Barcelona, Spain, in September. Nadine Pernodet, PhD, Senior Vice President, Bioscience, ELC, and Estée Lauder brand Lead Scientist, addressed innovation in the beauty industry in a lecture entitled, "Harnessing Epigenetics: from Anti-Aging to Age Reversal." Mei Yu, MD, PhD, Executive Director, Clinical Translation, Global Clinical & Consumer Science, Global R&D, ELC, presented a translational clinical study titled, "Development and validation of post-inflammatory hyperpigmentation (PIH) model in multi-ethnicities using different induction methods."

Key Points: 
  • Nadine Pernodet, PhD, Senior Vice President, Bioscience, ELC, and Estée Lauder brand Lead Scientist, addressed innovation in the beauty industry in a lecture entitled, "Harnessing Epigenetics: from Anti-Aging to Age Reversal."
  • Mei Yu, MD, PhD, Executive Director, Clinical Translation, Global Clinical & Consumer Science, Global R&D, ELC, presented a translational clinical study titled, "Development and validation of post-inflammatory hyperpigmentation (PIH) model in multi-ethnicities using different induction methods."
  • She also explained that, with the right technologies, understanding the positive and negative epigenetic signals provides the ability to reverse skin aging.
  • This body of research is central to the ongoing development of approaches that enable innovations to shift from anti-aging to age reversal.

The Estée Lauder Companies Launches 2023 Breast Cancer Campaign: Beautifully United to Help End Breast Cancer

Retrieved on: 
Friday, September 29, 2023
Women, Cosmetics, Retail, Research, Oncology, Tourist Attractions, Environmental, Social and Governance (ESG), Luxury, Fund Raising, Consumer, Foundation, Professional Services, Science, Social Media, Philanthropy, Health, Communications, Travel, Breast Cancer Awareness Month, Beauty, PARIS, Education, Empire State Building, Health equity, Cancer, Woman, Bobbi Brown, Medicine, Breast, Aveda, Clinique, BCRF, Patient, Breast cancer, ELC, BrainScope Company, Inc., Illuminate, Biology, Breast Cancer Research Foundation, Eiffel Tower, Evelyn Lauder, Bumble, Breast Cancer Campaign, Disease, Pink ribbon, Birth control, Campaign

For more than 30 years, The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) has been dedicated to advancing the possibility of a breast cancer-free world for all.

Key Points: 
  • For more than 30 years, The Estée Lauder Companies’ Breast Cancer Campaign (The Campaign) has been dedicated to advancing the possibility of a breast cancer-free world for all.
  • This October, The Estée Lauder Companies (ELC) honors Breast Cancer Awareness Month by launching The Campaign in support of the global breast cancer community.
  • Together, The Estée Lauder Companies’ Breast Cancer Campaign and The Estée Lauder Companies Charitable Foundation (ELCCF) have funded more than $118 million globally for life saving research, education, and medical services, with more than $93 million funding medical research through the Breast Cancer Research Foundation (BCRF).
  • The call to end breast cancer is more urgent than ever as breast cancer is the most commonly diagnosed cancer worldwide.

BrainScope Receives Investment from the Alzheimer’s Drug Discovery Foundation for Alzheimer's Prediction Biomarker

Retrieved on: 
Tuesday, September 19, 2023
Research, Nursing, Medical Devices, Medical Supplies, Hospitals, FDA, Biotechnology, Health, Science, Other Science, Weil, Concussion, CT, ABS Capital Partners, IDEC, Northwell Health, General partnership, Medicine, Brain, Biomarker, BrainScope Company, Inc., Weil, Gotshal & Manges, Aria, The Manges, MRI, Traction, Patient, AbbVie, Stanford University Medical Center, Machine learning, Rituximab, Artificial intelligence, Sport, Johns Hopkins, Trauma, ALS, Ibrutinib, Computer security, Medical imaging, Pharmaceutical industry, Biogen, Pharmacyclics

Brain diagnostics innovator BrainScope announced today a new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) in BrainScope’s current Series B equity financing round.

Key Points: 
  • Brain diagnostics innovator BrainScope announced today a new investment from the Alzheimer’s Drug Discovery Foundation (ADDF) in BrainScope’s current Series B equity financing round.
  • This investment supports the ongoing development of a new Artificial Intelligence / Machine Learning derived brain-activity based biomarker to predict future onset of Alzheimer’s.
  • "The global market for Alzheimer’s disease treatments is expected to rise to over $13 billion by 2030.
  • BrainScope also announced the appointment of three prominent individuals to its Board of Directors: Michael A. Epstein, Richard A. Miller MD, and Ralph Terkowitz.

Decibel Expands Global Footprint with Agreement to Supply Medical Cannabis to 4C LABS for Distribution in the United Kingdom

Retrieved on: 
Wednesday, August 30, 2023
Partnership, AB, BrainScope Company, Inc., Attention, BC Cannabis Stores, Good, Patient, Decibel, Cannabis, United Kingdom, Medical cannabis, Growth, The Company, LABS, Health, Drug, Qwest

Decibel to supply 4C LABS with Qwest branded, craft-quality Medical Cannabis for distribution to UK medical cannabis patients

Key Points: 
  • Decibel to supply 4C LABS with Qwest branded, craft-quality Medical Cannabis for distribution to UK medical cannabis patients
    "We are excited to partner with 4C LABS, a leading organization in the growing medical cannabis industry in the UK, that echoes Decibel's commitment to quality and patient care.
  • "Decibel's success with Qwest flower products in Canada and in Israel's medical market reinforces the demand for premium cannabis products and the reputation we have built to service that demand."
  • "4C LABS is building a patient focused best-in-class product line for the UK & Channel Islands, the Qwest craft flower line strengthens the top end of the 4C LABS product offerings.
  • Decibel's innovative craft quality Qwest flower products will fill an empty segment in the UK market and bring a world class BC Cannabis product to UK patients," said Greg Dobbin, CEO 4C LABS.

The Healing Company Forges Strategic Partnership with Althea DRF Lifesciences

Retrieved on: 
Thursday, August 24, 2023
Pharmacy, Partnership, Biotechnology, CPG, Cancer, Quality of life, BrainScope Company, Inc., Immunity, OTCQB, Research, Name, Acquisition, Entrepreneurship, Althea, Hospital, Fine chemical, Ayurveda

New York, NY, Aug. 24, 2023 (GLOBE NEWSWIRE) -- The Healing Company Inc. (OTCQB: HLCO) (“The Healing Company” or the “Company”) today announced a strategic partnership with Althea DRF Lifesciences, a renowned biosciences research center supported by the Burman family, majority shareholders of one of the largest Indian consumer packaged goods (CPG) companies and the largest Ayurvedic company worldwide with a $12 billion market capitalization.

Key Points: 
  • New York, NY, Aug. 24, 2023 (GLOBE NEWSWIRE) -- The Healing Company Inc. (OTCQB: HLCO) (“The Healing Company” or the “Company”) today announced a strategic partnership with Althea DRF Lifesciences, a renowned biosciences research center supported by the Burman family, majority shareholders of one of the largest Indian consumer packaged goods (CPG) companies and the largest Ayurvedic company worldwide with a $12 billion market capitalization.
  • The partnership will aim to accelerate The Healing Company’s growth and product innovation as it pursues its bold vision to bring integrated healing to the world, helping millions improve their quality of life.
  • Spearheaded by more than 100 multidisciplinary experts, the pioneering research and development team at Althea DRF Lifesciences will provide clinical rigor and validation to The Healing Company’s expanding portfolio of integrated healing offerings.
  • Althea DRF Lifescience’s experience delivering scalable solutions will also bolster The Healing Company’s strategic and operational capabilities, fueling the company’s M&A endeavors and propelling growth in a market primed for disruption.

The Estée Lauder Companies Shares New Preclinical and Clinical Findings at World Congress of Dermatology Spanning Emerging Research Areas that Support Skin Health and Longevity

Retrieved on: 
Thursday, July 6, 2023
Histology, La mer, Senior, Skin care, Xeroderma, SIRT2, 3D, Elastin, Clinical trial, Enzyme, EL, Ageing, Glycation, SIRT, AGE, Woman, Hyaluronic acid, Research, Sirtuin, Science, Thought, DE, Clinique, Congress, Parity, Beauty, Erythema, UV, ELC, Randomized controlled trial, Irritation, Hyperpigmentation, BrainScope Company, Inc., Advanced glycation end-product, Ozone, Knowledge, Poster, R, Longevity, Autostereogram, Human, NYSE, Identity matrix, Skin, N-Acetylglucosamine, Cosmetics, Medical imaging, Dietary supplement, Medical device, Dermatology

NEW YORK, July 6, 2023 /PRNewswire/ -- The Estée Lauder Companies Inc. (ELC) (NYSE: EL) today announced that the company and several of its brands presented a range of novel preclinical and clinical findings at the 25th World Congress of Dermatology, held this week in Singapore. The poster and satellite symposium presentations reflect a strong portfolio of prestige beauty and skin care brands effectively translating biological learnings and progressive research efforts into meaningful innovation, including better methods to care for and protect skin.

Key Points: 
  • With rapidly emerging knowledge and advancements from the dermatologic and scientific communities, the science of skin care has never been more important," said Lisa Napolione, Senior Vice President, Global Research & Development (R&D).
  • "As we live longer, research on health span and longevity will only accelerate.
  • To meet these innovation challenges, we are thinking differently, and in a manner enabled by novel science across all our global laboratories and clinics."
  • Using 3D skin models, researchers studied the anti-glycation properties of 6 compounds to determine their capacities to reduce auto-fluorescence in 3D skin models.

The Estée Lauder Companies to Present Novel Scientific Data at World Congress of Dermatology

Retrieved on: 
Wednesday, June 14, 2023
University, Senior, Sirtuin, Skin care, EL, Ageing, Longevity, Woman, Research, Toxicology, Inflammation, Doctor of Philosophy, Science, Chemistry, Congress, WCD, Publishing, Laboratory, ELC, University of California, Berkeley, Engineering, BrainScope Company, Inc., Physics, Biology, Poster, R, Science and technology in Asia, NYSE, Skin, Pharmaceutical industry, Cosmetics, List of life sciences, Dermatology

NEW YORK, June 14, 2023 /PRNewswire/ -- The Estée Lauder Companies Inc. (ELC) (NYSE: EL) today announced that the company and its brands will present at the 25th World Congress of Dermatology (WCD) in Singapore from July 3-8, 2023. ELC researchers across 3 brands and ELC Research & Development (R&D) will share novel clinical and preclinical results that demonstrate scientific innovation and leadership across emerging areas of skin health and anti-aging in the form of 5 poster presentations and a satellite symposium during this global event, which takes place every 4 years.

Key Points: 
  • NEW YORK, June 14, 2023 /PRNewswire/ -- The Estée Lauder Companies Inc. (ELC) (NYSE: EL) today announced that the company and its brands will present at the 25th World Congress of Dermatology (WCD) in Singapore from July 3-8, 2023.
  • "The breadth and depth of data to be presented further reflects our robust combined R&D and clinical testing capabilities.
  • These highly integrated areas of focus support our exploration of new ingredients or methodologies to ultimately help shape and advance the skin care landscape."
  • The company has 75 years of formulation authority and is deeply integrated into the scientific community, regularly presenting at leading events and publishing in peer-reviewed journals.

Ukrainian physicians on the frontline amongst 900 presenters at the 20th Annual World Congress of Society for Brain Mapping and Therapeutics (SBMT) in LA

Retrieved on: 
Wednesday, February 1, 2023
Karma, Linda, Joint Chiefs of Staff, Student, Society for Brain Mapping and Therapeutics, Baptist Health, Physician, GPS, Uday Chopra, Multimedia, Army Group South, Cancer, Society, UCR, Neurosurgery, Neurology, Surgeon, Medicines and Healthcare products Regulatory Agency, Genetics, Spine, Keck School of Medicine of USC, DRS, NORA, Brain mapping, SBMT, Pentagon, Baptist Health South Florida, Los Angeles Convention Center, Therapy, WBMF, UCSD, Medicine, Psychiatric Rehabilitation Association, Science, USC, Olympus, Cadaver, DSM-IV codes, Convention, Stryker, Loma Linda University, Mental, BrainScope Company, Inc., Gun violence, US, Mental health, Psychology, LOS, Nursing, Medical imaging, Brain, Instituto de Biologia Molecular e Celular

LOS ANGELES, Feb. 1, 2023 /PRNewswire/ -- Last year, the Society for Brain Mapping and Therapeutics (SBMT) established a task force to help Ukraine with medical humanitarian missions including engaging physicians and neurosurgeons in combat casualty care and medical supply support. This year, the Ukrainian Medical Team supported by SBMT will present their work at the 20th Annual World Congress of SBMT (Brain, Spine and Mental Health) at the LA Convention Center on Feb. 16-19, 2023.  

Key Points: 
  • This year, the Ukrainian Medical Team supported by SBMT will present their work at the 20th Annual World Congress of SBMT (Brain, Spine and Mental Health) at the LA Convention Center on Feb. 16-19, 2023.
  • "We are using our convention to not only advance the neurotechnology to treat neuropsychiatric, spine and brain disorders but impact people in war zones through our humanitarian missions."
  • Said, Dr. Vicky Yamamoto, 20th President, Executive Director of SBMT, and a cancer scientist at Keck School of Medicine of USC.
  • The Convention will have two Keynote panels on "Advanced Cancer Therapy" and "The Psychology of the Brain and Gun Violence."

iMD Companies Announces Partnership With Cudo Ventures, the Global Leader in Providing Innovative Solutions for Cryptocurrency Mining

Retrieved on: 
Wednesday, February 8, 2023
Bitcoin, BrainScope Company, Inc., IMD, AI, Partnership, Mining, Carbon, OTC, Cloud computing, BTC, Cudos, Cryptocurrency

CARSON CITY, NV, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – iMD Companies Inc. (OTC:ICBU) announced today a partnership with Cudo Ventures, the global leader in providing innovative solutions for cryptocurrency mining.

Key Points: 
  • CARSON CITY, NV, Feb. 08, 2023 (GLOBE NEWSWIRE) -- via NewMediaWire – iMD Companies Inc. (OTC:ICBU) announced today a partnership with Cudo Ventures, the global leader in providing innovative solutions for cryptocurrency mining.
  • Cudo Ventures will be their strategic partner and advisor for activities related to Cudo’s cryptocurrency miner, mining, cloud computing platforms, and web3.
  • Cudo is the global leader in providing monetization applications for users around the world providing an elite turnkey mining platform.
  • Cudo is the only way to go for crypto mining, web3, and all of their wonderfully truly innovative solutions!